Canine parvovirus-like particles, a novel nanomaterial for tumor targeting

Journal of Nanobiotechnology

Volumn 4, Issue , 2006, Pages

  Singh, Pratik ^a   Destito, Giuseppe ^a,b   Schneemann, Anette ^a   Manchester, Marianne ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL MODIFICATION; MATHEMATICAL MODELS; NANOSTRUCTURED MATERIALS; NANOTECHNOLOGY; ONCOLOGY; TUMORS; VIRUSES;

CANINE PARVOVIRUS; NANOTHERAPEUTICS; TRANSFERRIN RECEPTORS;

BIOTECHNOLOGY;

ANTINEOPLASTIC AGENT; CAPSID PROTEIN; FLUORESCENT DYE; LYSINE; TRANSFERRIN RECEPTOR; VIRUS DNA;

ANIMAL CELL; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; BINDING AFFINITY; CELL ADHESION; CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DERIVATIZATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NANOTECHNOLOGY; NONHUMAN; PARVOVIRUS; PROTEIN MODIFICATION; RECEPTOR BINDING; TARGET CELL; TUMOR CELL; VIRUS PARTICLE;

ANIMALIA; CANINE PARVOVIRUS; DNA VIRUSES; MIRIDAE; PARVOVIRUS;

EID: 33644640159     PISSN: 14773155     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-4-2     Document Type: Article

References (54)

1. Fennelly D: Dose intensity in advanced ovarian cancer: have we answered the question? Clin Cancer Res 1995, 1:575-582.
2. Myers CE, Chabner BA: Anthracyclins. In Cancer chemotherapy-principles and practice Edited by: Chabner, B. A., Collins, J. M.. Philadelphia, Lippincott; 1990:256-381.
3. Dubowchik GM, Walker MA: Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 1999, 83:67-123.
4. Feng SS, Chien S: Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chemical Engineering Science 2003, 58:4087-4114.
5. Brannon-Peppas L, Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Advanced drug delivery reviews 2004, 56:1649-1659.
6. Ferrari M: Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
7. Medina OP, Zhu Y, Kairemo K: Targeted liposomal drug delivery in cancer. Curr Pharm Des 2004, 10:2981-2989.
8. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny C.G, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD: Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003, 21:778-784.
9. Muldoon LL, Neuwelt EA: BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. J Neurooncol 2003, 65:49-62.
10. Brown WL, Mastico RA, Wu M, Heal KG, Adams CJ, Murray JB, Simpson JC, Lord JM, Taylor-Robinson AW, Stockley PG: RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 2002, 45:371-380.
11. Abbing A, Blaschke UK, Grein S, Kretschmar M, Stark CM, Thies MJ, Walter J, Weigand M, Woith DC, Hess J, Reiser CO: Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem 2004, 279:27410-27421.
12. Pattenden LK, Middelberg AP, Niebert M, Lipin DI: Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol 2005, 23(10):523-529.
13. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JRJ: Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005, 65:5317-5324.
14. Singh P, Gonzalez MJ, Manchester M: Viruses and their uses in nanotechnology. Drug Development Research 2006.
15. Wang Q, Kaltgrad E, Lin T, Johnson JE, Finn MG: Natural supramolecular building blocks: wild-type cowpea mosaic virus. Chem Biol 2002, 9(7):805-811.
16. Peabody DS: A viral platform for chemical modification and multivalent display. J Nanobiotechnology 2003, 1:5.
17. Hooker JM, Kovacs EW, Francis MB: Interior surface modification of bacteriophage MS2. J Am Chem Soc 2004, 126:3718-3719.
18. Basu G, Allen M, Willits D, Young M, Douglas T: Metal binding to cowpea chlorotic mottle virus using terbium(III) fluorescence. J Biol Inorg Chem 2003, 8:721-725.
19. Sen Gupta S, Kuzelka J, Singh P, Lewis WG, Manchester M, Finn MG: Accelerated bioorthogonal cojugation: A practical method for ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconj Chem 2005, 16(6):1572-1579.
20. Chen L, Zurita AJ, Ardelt PU, Giordano RJ, Arap W, Pasqualini R: Design and validation of a bifunctional ligand display system for receptor targeting. Chemistry & Biology 2004, 11:1081-1091.
21. Chatterji A, Ochoa W, Paine M, Ratna BR, Johnson JE, Lin T: New Addresses on an addressable virus nanoblock: uniquely reactive lys residues on cowpea mosaic virus. Chemistry and Biology 2004, 11:855-863.
22. Chatterji A, Ochoa W, Shamieh L, Salakian SP, Wong SM, Clingon G, Ghosh P, Lint T, Johnson J: Chemical conjugation of heterologous proteins on the surface of cowpea mosaic virus. Bioconjug Chem 2004, 15:807-813.
23. Portney NG, Singh K, Chaudhary, S., Destito G, Schneemann A, Manchester M, Ozkan M: Organic and inorganic nanoparticle hybrids. Langmuir 2005, 21:2098-2103.
24. Henning P, Andersson KM, Frykholm K, Ali A, Magnusson MK, Nygren PA, Granio O, Hong SS, Boulanger P, Lindholm L: Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther 2005, 12:211-224.
25. Gleiter S, Lilie H: Cell-type specific targeting and gene expression using a variant of polyoma VP 1 virus-like particles. Biol Chem 2003, 384:.
26. Tsao J, Chapman MS, Agbandje M, Keller W, Smith K, Wu H, Luo M, Smith TJ, Rossmann MG, Compans RW, Parrish CR: The three-dimensional structure of canine parvovirus and its functional implications. Science 1991, 251:1456-1464.
27. Yuan W, Parrish CR: Canine parvovirus capsid assembly and differences in mammalian and insect cells. Virology 2001, 279:546-557.
28. Parker JS, Murphy WJ, Wang D, O'Brien SJ, Parrish CR: Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J Virol 2001, 75:3896-3902.
29. Gomme PT, McCann KB, Bertolini. J: Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 2005, 10:267-273.
30. Inoue T, Cavanaugh PG, Steck PA, Brunner N, Nicolson GL: Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 1993, 156:212-217.
31. Bridges KR, Smith BR: Discordance between transferrin receptor expression and susceptibility to lysis by natural killer cells. J Clin Invest 1985, 76:913-918.
32. Becker A, Riefke B, Ebert B, Sukowski U, Rinneberg H, Semmler W, Licha K: Macromolecular contrast agents for optical imaging of tumors: comparison of indotricarbocyanine-labeled human serum albumin and transferrin. Photochem Photobiol 2000, 72:234-241.
33. Sato Y, Yamauchi N, Takahashi M, Sasaki K, Fukaura J, Neda H, Fujii S, Hirayama M, Itoh Y, Koshita Y, Kogawa K, Kato J, Sakamaki S, Niitsu Y: In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. FASEB J 2000, 14:2108-2118.
34. Ryschich E, Huszty G, Knaebel HP, Hartel M, Buchler MW, Schmidt J: Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer 2004, 40:1418-1422.
35. Qian Z, Li H, Sun H, Ho K: Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharm Rev 2002, 54:561-587.
36. Hogemann-Savellano D, Bos E, Blondet C, Sato F, Abe T, Josephson L, Weissleder R, Gaudet J, Sgroi D, Peters PJ, Basilion JP: The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 2003, 5:495-506.
37. Maranga L, Rueda P, Antonis AF, Vela C, Langeveld, J.P., Casal JI, Carrondo MJ: Large scale production and downstream processing of a recombinant porcine parvovirus vaccine. Appl Microbiol Biotechnol 2002, 59:45-50.
38. Sasnauskas K, Bulavaite A, Hale A, Jin L, Knowles WA, Gedvilaite A, Dargeviciute A, Bartkeviciute D, Zvirbliene A, Staniulis J, Brown DW, Ulrich R: Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae. Intervirology 2002, 45:308-317.
39. Li HZ Gang HY, Sun QM, Liu X, Ma YB, Sun MS, Dai CB: Production in Pichia pastoris and characterization of genetic engineered chimeric HBV/ HEV virus-like particles. Chin Med Sci J 2004, 19:78-83.
40. Wu HL, Chen PJ, Mu JJ, Chi WK, Kao TL, Hwang LH, Chen DS: Assembly of hepatitis delta virus-like empty particles in yeast. Virology 1997, 236:374-381.
41. Brumfield S, Willits D, Tang L, Johnson JE, Douglas T, Young M: Heterologous expression of the modified coat protein of Cowpea chlorotic mottle bromovirus results in the assembly of protein cages with altered architectures and function. J Gen Virol 2004, 85:1049-1053.
42. Krishna NK, Marshall D, Schneemann A: Analysis of RNA packaging in wild-type and mosaic protein capsids of flock house virus using recombinant baculovirus vectors. Virology 2003, 305:10-24.
43. Hsu C, Singh P, Ochoa W, Manayani DJ, Schneeman A, Reddy V: Characterization of polymorphism displayed by the coat protein mutants of tomato bushy stunt virus. Virology 2006:manuscript accepted.
44. Parker JS, Parrish CR: Canine parvovirus host range is determined by the specific conformation of an additional region of the capsid. J Virol 1997, 71:9214-9222.
45. Suikkanen S, Saajarvi K, Hirsimaki J, Valilehto O, Reunanen H, Vihinen-Ranta M, Vuento M: Role of recycling endosomes and lysosomes in dynein-dependent entry of canine parvovirus. J Virol 2002, 76:4401-4411.
46. McGraw TE, Greenfield L, Maxfield FR: Functional expression of the human transferrin receptor cDNA in Chinese hamster ovary cells deficient in endogenous transferrin receptor. J Cell Biol 1987, 105:207-214.
47. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, Sinko PJ, Stein S, Farmanfarmaian A, Minko T: Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A 2005, 102:12962-12967.
48. Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R, Hermiston T, Ulbrich K, Fisher KD, Seymour LW: Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 2004, 11:1256-1263.
49. Raja KS, Wang Q, Gonzalez MJ, Manchester M, Johnson JE, Finn MG: Hybrid virus-polymer materials. I. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 2003, 4:472-476.
50. Netter HJ, Woo WP, Tindle R, Macfarlan RI, Gowans EJ: Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine. Vaccine 2003, 21:2692-2697.
51. Reddy VS, Natarajan P, Okerberg B, Li K, Damodaran KV, Morton RT, Brooks CL, Johnson JE: Virus Particle Explorer (VIPER), a website for virus capsid structures and their computational analyses. http://viperdb.scripps.edu. J Virol 2001, 75:11943-11947.
52. http://www.chimera.org.
53. Brooks B, Bruccoleri B, Olafson D, States D, Swaminathan S, Karplus M: CHARMM: a program for macromolecular energy, minimization and dynamics calculation. J Comp Chem 1983, 4:183-217.
54. http://www.ks.uiuc.edu/Research/vmd.